Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Savara Inc (SVRA)

Savara Inc (SVRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 158,249
  • Shares Outstanding, K 113,848
  • Annual Sales, $ 260 K
  • Annual Income, $ -49,620 K
  • 60-Month Beta 1.23
  • Price/Sales 567.03
  • Price/Cash Flow N/A
  • Price/Book 1.07
Trade SVRA with:

Options Overview

Details
  • Implied Volatility 176.82%
  • Historical Volatility 78.87%
  • IV Percentile 27%
  • IV Rank 8.03%
  • IV High 1,348.82% on 11/18/20
  • IV Low 74.51% on 11/16/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 153
  • Volume Avg (30-Day) 165
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 4,625
  • Open Int (30-Day) 3,999

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.09
  • Number of Estimates 4
  • High Estimate -0.07
  • Low Estimate -0.14
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2400 +4.44%
on 08/23/21
1.6000 -19.06%
on 09/03/21
+0.0550 (+4.44%)
since 08/20/21
3-Month
1.1600 +11.64%
on 08/18/21
1.8300 -29.23%
on 06/21/21
-0.4750 (-26.84%)
since 06/18/21
52-Week
0.9952 +30.12%
on 11/16/20
3.5800 -63.83%
on 03/16/21
+0.0250 (+1.97%)
since 09/18/20

Most Recent Stories

More News
Savara to Participate in Two Upcoming Investor Healthcare Conferences

--Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

SVRA : 1.2900 (-7.19%)
Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

SVRA : 1.2900 (-7.19%)
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

SVRA : 1.2900 (-7.19%)
Savara Reports Second Quarter 2021 Financial Results and Provides Business Update

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the second quarter ending June 30, 2021 and provided a...

SVRA : 1.2900 (-7.19%)
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study

Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.

CANF : 1.7000 (-2.30%)
XNCR : 33.82 (-2.17%)
SVRA : 1.2900 (-7.19%)
ACER : 2.52 (+2.44%)
Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial....

SVRA : 1.2900 (-7.19%)
Implied Volatility Surging for Savara (SVRA) Stock Options

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

SVRA : 1.2900 (-7.19%)
Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare & Orphan Disease...

SVRA : 1.2900 (-7.19%)
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that on May 11, 2021, the Compensation Committee of the Company's Board of Directors...

SVRA : 1.2900 (-7.19%)
Savara Reports First Quarter 2021 Financial Results and Provides Business Update

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the first quarter ending March 31, 2021 and provided a...

SVRA : 1.2900 (-7.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States.

See More

Key Turning Points

3rd Resistance Point 1.5767
2nd Resistance Point 1.4833
1st Resistance Point 1.4367
Last Price 1.2900
1st Support Level 1.2967
2nd Support Level 1.2033
3rd Support Level 1.1567

See More

52-Week High 3.5800
Fibonacci 61.8% 2.5926
Fibonacci 50% 2.2876
Fibonacci 38.2% 1.9826
Last Price 1.2900
52-Week Low 0.9952

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar